Conference Updates from IDWeek in San Francisco and IAS in Amsterdam
W. David Hardy, MD
Adjunct Professor of Medicine, Division of Infectious Diseases
Johns Hopkins University School of Medicine, Baltimore, MD
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2018. All rights reserved.
David Hardy received his medical degree from Baylor College of Medicine, Houston, TX and completed his residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California. Early in the AIDS epidemic, he completed a clinical fellowship in infectious diseases/immunology and clinical research at the UCLA School of Medicine under the direction of Dr Michael Gottlieb, the physician who recognized and reported the first cases of AIDS. Later he also completed a laboratory fellowship in molecular retrovirology at the David Geffen School of Medicine at UCLA. Dr. Hardy has cared for persons with HIV infection since 1982 and conducted research on HIV and related diseases since 1984. Initially, he focused on treatment and prevention of opportunistic infections and currently on antiretroviral agents, immunotherapies and hepatitis treatments as well as retroviral vector research and gene therapy. Dr Hardy currently serves as Chair-Elect of the Board of Directors of the HIV Medicine Association (HIVMA) and will advance to Chair in 2018. Dr. Hardy also serves as Chair of the Education Committee of the American Academy of HIV Medicine (AAHIVM). He served as editor-in-chief of AAHIVM’s comprehensive clinical textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2007, 2008, 2012, 2017 and 2019.
At the completion of this educational session, learners will:
- Better appreciate new data regarding diagnosis and treatment of coinfections seen in PLWH.
- Understand new developments regarding diagnosis, prevention and treatment of comorbidities seen in PLWH.
- Be aware of how these coinfections and comorbidities impact mortality and morbidity of PLWH.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
